Literature DB >> 7726506

Subinhibitory concentrations of cefpodoxime alter membrane protein expression of Actinobacillus actinomycetemcomitans and enhance its susceptibility to killing by neutrophils.

P J Baker1, W F Busby, M E Wilson.   

Abstract

The aim of the present study was to determine the effect of the antibiotic cefpodoxime on the gram-negative periodontopathic microorganism Actinobacillus actinomycetemcomitans and its interaction with elements of the host immune system. Growth of A. actinomycetemcomitans in subinhibitory concentrations of cefpodoxime induced morphological changes in the bacteria, causing the organisms to grow as filaments rather than coccobacilli. Growth in cefpodoxime did not render these bacteria susceptible to killing by serum, nor did it abrogate the requirement for serum opsonins to support the bactericidal activity of neutrophils. Cefpodoxime enhanced the susceptibility of A. actinomycetemcomitans to the bactericidal activity of neutrophils. In the presence of suitable opsonins, neutrophils were able to kill four times as many cefpodoxime-induced A. actinomycetemcomitans filaments as untreated A. actinomycetemcomitans CFU. This effect was due to antibiotic actions on the bacterium and not on the neutrophil. At inhibitory concentrations, the bactericidal activities of cefpodoxime and neutrophils were additive, and cefpodoxime did not interfere with the normal functioning of the neutrophils. Concomitant with these morphological and functional changes, the expression of two outer membrane proteins (66 and 29 kDa) and one inner membrane protein (57 kDa) was decreased in A. actinomycetemcomitans grown in cefpodoxime. The concentration range over which cefpodoxime is effective against A. actinomycetemcomitans in vivo may be extended by the ability of subinhibitory concentrations to enhance the susceptibility of this organism to host immune defenses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7726506      PMCID: PMC162551          DOI: 10.1128/AAC.39.2.406

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Host responses in periodontal diseases.

Authors:  R J Genco; J Slots
Journal:  J Dent Res       Date:  1984-03       Impact factor: 6.116

Review 2.  Role of the polymorphonuclear leukocyte in periodontal health and disease.

Authors:  D R Miller; I B Lamster; A I Chasens
Journal:  J Clin Periodontol       Date:  1984-01       Impact factor: 8.728

Review 3.  Effects of antimicrobial and antineoplastic drugs on the phagocytic and microbicidal function of the polymorphonuclear leukocyte.

Authors:  L A Mandell
Journal:  Rev Infect Dis       Date:  1982 May-Jun

Review 4.  Sublethal concentrations of antibiotics, effects on bacteria and the immune system.

Authors:  B A Atkinson; L Amaral
Journal:  Crit Rev Microbiol       Date:  1982       Impact factor: 7.624

Review 5.  Antibiotics in the treatment of human periodontal diseases.

Authors:  R J Genco
Journal:  J Periodontol       Date:  1981-09       Impact factor: 6.993

6.  Bactericidal effect of pooled human serum on Bacteroides melaninogenicus, Bacteroides asaccharolyticus and Actinobacillus actinomycetemcomitans.

Authors:  G Sundqvist; E Johansson
Journal:  Scand J Dent Res       Date:  1982-02

7.  Antibiotic susceptibility of anaerobic bacteria from the human oral cavity.

Authors:  P J Baker; R T Evans; J Slots; R J Genco
Journal:  J Dent Res       Date:  1985-10       Impact factor: 6.116

8.  Synergism of cephalosporins at subinhibitory concentrations and polymorphonuclear leukocytes on phagocytic killing of Escherichia coli and its mode of action.

Authors:  Y Watanabe; S Tawara; Y Mine; H Kikuchi; S Goto; S Kuwahara
Journal:  J Antibiot (Tokyo)       Date:  1986-02       Impact factor: 2.649

Review 9.  Actinobacillus actinomycetemcomitans in human periodontal disease.

Authors:  J J Zambon
Journal:  J Clin Periodontol       Date:  1985-01       Impact factor: 8.728

10.  In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.

Authors:  H S Sader; R N Jones; J A Washington; P R Murray; E H Gerlach; S D Allen; M E Erwin
Journal:  Diagn Microbiol Infect Dis       Date:  1993 Aug-Sep       Impact factor: 2.803

View more
  1 in total

1.  Mature Biofilm Degradation by Potential Probiotics: Aggregatibacter actinomycetemcomitans versus Lactobacillus spp.

Authors:  Norzawani Jaffar; Yuya Ishikawa; Kouhei Mizuno; Toshinori Okinaga; Toshinari Maeda
Journal:  PLoS One       Date:  2016-07-20       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.